Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Gastroparesis Drugs Market

Gastroparesis Drugs Market Share

Report ID: GMI9322
Published Date: May 2024
Report Format: PDF

Download Free Sample

Gastroparesis Drugs Market Share

The competitive landscape of the gastroparesis drugs industry is characterized by the presence of established pharmaceutical companies that manufacture drugs used for gastroparesis vying for market share. Key players are engaging in strategic initiatives such as new product launch, acquisitions, investment, and partnerships to strengthen their product portfolio. Companies are actively adopting a multi-pronged approaches to address the rising demand for effective gastroparesis drugs.

Gastroparesis Drugs Market Companies

Prominent players operating in the gastroparesis drugs industry are as mentioned below:

Abbott Laboratories
AbbVie Inc.
AstraZeneca PLC
Bayer AG
Cipla Ltd.
Evoke Pharma
Pfizer Inc.
Salix Pharmaceuticals
Takeda Pharmaceutical, Inc.
Teva Pharmaceutical Inc.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Gastroparesis drugs industry size was USD 5.9 billion in 2023 and will depict a 5% CAGR from 2024 to 2032 due to the increasing prevalence of gastroparesis globally, particularly among diabetic patients, rising awareness about the condition, and advancements in diagnostic techniques.

The diabetes gastroparesis segment captured 44.6% of the market share in 2023, driven by the escalating prevalence of diabetes worldwide coupled with the consequential rise in gastroparesis cases among diabetic patients.

North America gastroparesis drugs industry will record USD 3.5 billion by 2032, attributed to advanced healthcare infrastructure, high awareness about gastroparesis, and robust R&D activities.

Key gastroparesis drug firms are Abbott Laboratories, AbbVie Inc., AstraZeneca PLC, Bayer AG, Cipla Ltd., Evoke Pharma, Pfizer Inc., Salix Pharmaceuticals, Takeda Pharmaceutical, Inc., and Teva Pharmaceutical Inc., among others.